Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Ultragenyx reported revenue of $166.5 million for the quarter ended June 2025, reflecting a 13.2% increase year-over-year and a surprise of +2.94% over the Zacks Consensus Estimate of $161.74 million [1] - The company's EPS was -$1.17, an improvement from -$1.52 in the same quarter last year, with an EPS surprise of +7.87% compared to the consensus estimate of -$1.27 [1] Revenue Breakdown - Dojolvi product sales reached $23.21 million, exceeding the average estimate of $22.38 million by analysts, marking a +19.9% change from the previous year [4] - Evkeeza product sales were $14.57 million, significantly surpassing the estimated $11.08 million, representing an impressive +85.5% increase year-over-year [4] - Mepsevii product sales totaled $8.31 million, slightly below the average estimate of $8.64 million [4] - Total Crysvita revenue was $120.41 million, exceeding the average estimate of $118.04 million by analysts [4] - Overall product sales amounted to $80.82 million, which was below the estimated $84.66 million, but still showed a +9.5% change compared to the previous year [4] - Royalty revenue reached $85.68 million, surpassing the average estimate of $77.43 million, reflecting a +17% increase year-over-year [4] Stock Performance - Ultragenyx shares have declined by -28.2% over the past month, contrasting with a +1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]